Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 223

1.

Oxytocin enhances observational fear in mice.

Pisansky MT, Hanson LR, Gottesman II, Gewirtz JC.

Nat Commun. 2017 Dec 13;8(1):2102. doi: 10.1038/s41467-017-02279-5.

2.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

PMID:
28854085
3.

Mice lacking the chromodomain helicase DNA-binding 5 chromatin remodeler display autism-like characteristics.

Pisansky MT, Young AE, O'Connor MB, Gottesman II, Bagchi A, Gewirtz JC.

Transl Psychiatry. 2017 Jun 13;7(6):e1152. doi: 10.1038/tp.2017.111.

4.

Animal models to improve our understanding and treatment of suicidal behavior.

Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT.

Transl Psychiatry. 2017 Apr 11;7(4):e1092. doi: 10.1038/tp.2017.50. Review.

5.

Schizophrenia spectrum personality disorders in psychometrically identified schizotypes at two-year follow-up.

Bolinskey PK, Smith EA, Schuder KM, Cooper-Bolinskey D, Myers KR, Hudak DV, James AV, Hunter HK, Novi JH, Guidi JP, Gonzalez Y, McTiernan EF, Arnold KM, Iati CA, Gottesman II.

Psychiatry Res. 2017 Jun;252:289-295. doi: 10.1016/j.psychres.2017.03.014. Epub 2017 Mar 8.

PMID:
28288440
6.

Stratifying empiric risk of schizophrenia among first degree relatives using multiple predictors in two independent Indian samples.

Bhatia T, Gettig EA, Gottesman II, Berliner J, Mishra NN, Nimgaonkar VL, Deshpande SN.

Asian J Psychiatr. 2016 Dec;24:79-84. doi: 10.1016/j.ajp.2016.08.015. Epub 2016 Aug 21.

7.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

8.

Epigenetic assimilation in the aging human brain.

Oh G, Ebrahimi S, Wang SC, Cortese R, Kaminsky ZA, Gottesman II, Burke JR, Plassman BL, Petronis A.

Genome Biol. 2016 Apr 28;17:76. doi: 10.1186/s13059-016-0946-8.

9.

Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds.

Homberg JR, Kyzar EJ, Scattoni ML, Norton WH, Pittman J, Gaikwad S, Nguyen M, Poudel MK, Ullmann JF, Diamond DM, Kaluyeva AA, Parker MO, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Brain Res Bull. 2016 Jul;125:79-91. doi: 10.1016/j.brainresbull.2016.04.015. Epub 2016 Apr 23. Review.

PMID:
27113433
10.

Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models.

Homberg JR, Kyzar EJ, Nguyen M, Norton WH, Pittman J, Poudel MK, Gaikwad S, Nakamura S, Koshiba M, Yamanouchi H, Scattoni ML, Ullman JF, Diamond DM, Kaluyeva AA, Parker MO, Klimenko VM, Apryatin SA, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Neurosci Biobehav Rev. 2016 Jun;65:292-312. doi: 10.1016/j.neubiorev.2016.03.013. Epub 2016 Apr 2. Review.

PMID:
27048961
11.

A Danish Twin Study of Schizophrenia Liability: Investigation from Interviewed Twins for Genetic Links to Affective Psychoses and for Cross-Cohort Comparisons.

Kläning U, Trumbetta SL, Gottesman II, Skytthe A, Kyvik KO, Bertelsen A.

Behav Genet. 2016 Mar;46(2):193-204. doi: 10.1007/s10519-015-9765-z. Epub 2015 Nov 4.

PMID:
26538243
12.

Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.

Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, Elliott S, Goldenberg L, Gottesman I, Grober ED, Guyatt GH, Holmes DT, Lee JC; Canadian Men’s Health Foundation Multidisciplinary Guidelines Task Force on Testosterone Deficiency.

CMAJ. 2015 Dec 8;187(18):1369-77. doi: 10.1503/cmaj.150033. Epub 2015 Oct 26. Review. No abstract available.

13.

Classical and Molecular Genetic Research on General Cognitive Ability.

McGue M, Gottesman II.

Hastings Cent Rep. 2015 Sep-Oct;45(5 Suppl):S25-31. doi: 10.1002/hast.495.

PMID:
26413945
14.

Endophenotypes for Alcohol Use Disorder: An Update on the Field.

Salvatore JE, Gottesman II, Dick DM.

Curr Addict Rep. 2015 Mar;2(1):76-90.

15.

Targeting drug sensitivity predictors: New potential strategies to improve pharmacotherapy of human brain disorders.

Kalueff AV, Stewart AM, Nguyen M, Song C, Gottesman II.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:76-82. doi: 10.1016/j.pnpbp.2015.05.004. Epub 2015 May 11. Review.

PMID:
25976211
16.

Targeting dynamic interplay among disordered domains or endophenotypes to understand complex neuropsychiatric disorders: Translational lessons from preclinical models.

Kalueff AV, Stewart AM, Song C, Gottesman II.

Neurosci Biobehav Rev. 2015 Jun;53:25-36. doi: 10.1016/j.neubiorev.2015.03.007. Epub 2015 Mar 24. Review.

PMID:
25813308
17.

Impact of depression on quality-adjusted life expectancy (QALE) directly as well as indirectly through suicide.

Jia H, Zack MM, Thompson WW, Crosby AE, Gottesman II.

Soc Psychiatry Psychiatr Epidemiol. 2015 Jun;50(6):939-49. doi: 10.1007/s00127-015-1019-0. Epub 2015 Feb 7.

18.

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC; EDITION 2 Study Investigators.

Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5.

PMID:
25193531
19.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.

PMID:
25190523
20.

Rethinking CNS disorders: time for new drug targets?

Kalueff AV, Stewart AM, Gottesman II.

Trends Pharmacol Sci. 2014 Oct;35(10):491-2. doi: 10.1016/j.tips.2014.07.007. Epub 2014 Aug 26. No abstract available.

PMID:
25169968

Supplemental Content

Loading ...
Support Center